These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 7505124

  • 1. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
    Pettengell R, Morgenstern GR, Woll PJ, Chang J, Rowlands M, Young R, Radford JA, Scarffe JH, Testa NG, Crowther D.
    Blood; 1993 Dec 15; 82(12):3770-7. PubMed ID: 7505124
    [Abstract] [Full Text] [Related]

  • 2. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
    Dreger P, Klöss M, Petersen B, Haferlach T, Löffler H, Loeffler M, Schmitz N.
    Blood; 1995 Nov 15; 86(10):3970-8. PubMed ID: 7579368
    [Abstract] [Full Text] [Related]

  • 3. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.
    Lickliter JD, Begley CG, Boyd AW, Szer J, Grigg AP.
    Leuk Lymphoma; 1994 Sep 15; 15(1-2):91-7. PubMed ID: 7532059
    [Abstract] [Full Text] [Related]

  • 4. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD.
    Clin Cancer Res; 1998 Feb 15; 4(2):311-6. PubMed ID: 9516916
    [Abstract] [Full Text] [Related]

  • 5. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C, Pettengell R, Ghielmini M, Radford JA, Morgenstern GR, Stern PL, Crowther D.
    Bone Marrow Transplant; 1995 Jun 15; 15(6):901-6. PubMed ID: 7581089
    [Abstract] [Full Text] [Related]

  • 6. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
    Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A.
    Lancet; 1996 Feb 10; 347(8998):353-7. PubMed ID: 8598700
    [Abstract] [Full Text] [Related]

  • 7. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G.
    Bone Marrow Transplant; 1998 May 10; 21(9):873-8. PubMed ID: 9613778
    [Abstract] [Full Text] [Related]

  • 8. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Smith RJ, Sweetenham JW.
    Exp Hematol; 1995 Dec 10; 23(14):1581-8. PubMed ID: 8542950
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
    Bone Marrow Transplant; 1999 Sep 10; 24(5):473-81. PubMed ID: 10482930
    [Abstract] [Full Text] [Related]

  • 10. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.
    Zeller W, Gutensohn K, Stockschläder M, Dierlamm J, Kröger N, Koehne G, Hummel K, Kabisch H, Weh HJ, Kühnl P, Hossfeld DK, Zander AR.
    Bone Marrow Transplant; 1996 May 10; 17(5):709-13. PubMed ID: 8733686
    [Abstract] [Full Text] [Related]

  • 11. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct 10; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 12. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb 10; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 13. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L.
    J Clin Oncol; 1997 Feb 10; 15(2):491-8. PubMed ID: 9053470
    [Abstract] [Full Text] [Related]

  • 14. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
    Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J.
    Blood; 1997 May 01; 89(9):3136-47. PubMed ID: 9129016
    [Abstract] [Full Text] [Related]

  • 15. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma.
    Jones HM, Jones SA, Watts MJ, Khwaja A, Mills W, Fielding A, Goldstone AH, Linch DC.
    J Clin Oncol; 1994 Aug 01; 12(8):1693-702. PubMed ID: 7518861
    [Abstract] [Full Text] [Related]

  • 16. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
    Zimmerman TM, Michelson GC, Mick R, Grinblatt DL, Williams SF.
    J Clin Apher; 1999 Aug 01; 14(1):31-4. PubMed ID: 10355661
    [Abstract] [Full Text] [Related]

  • 17. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL, Braine HG, Davis JM, Huelskamp AM, Schepers KG, Ohly K, Clarke B, Wright SK, Noga SJ, Davidson NE.
    J Clin Oncol; 1995 Mar 01; 13(3):705-14. PubMed ID: 7533827
    [Abstract] [Full Text] [Related]

  • 18. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
    Corato A, Ambrosetti A, Rossi B, Vincenzi C, Lambiase A, Perona G, Pizzolo G, de Wynter E, Nadali G.
    J Hematother Stem Cell Res; 2000 Oct 01; 9(5):673-82. PubMed ID: 11091491
    [Abstract] [Full Text] [Related]

  • 19. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
    Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R, Morgenstern GR, Scarffe JH, Crowther D.
    Br J Cancer; 1998 Apr 01; 77(8):1294-9. PubMed ID: 9579836
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
    Sheridan WP, Begley CG, To LB, Grigg A, Szer J, Maher D, Green MD, Rowlings PA, McGrath KM, Cebon J.
    Bone Marrow Transplant; 1994 Jul 01; 14(1):105-11. PubMed ID: 7524904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.